Inhibitors targeting Bruton’s tyrosine kinase in cancers: drug development advances
2020 · Leukemia · 240 citations
https://doi.org/10.1038/s41375-020-01072-6
T
Claim or correct this author profile
Claim this profile or suggest corrections to the name, affiliation, bio, photo, or paper titles. Approved changes appear as verified CitedEvidence overlays.
13
Papers
318
Citations
5
h-index
4
i10-index
Tingyu Wen is an academic researcher from Chinese Academy of Medical Sciences & Peking Union Medical College. The author has contributed to research in topics: Lymphoma Diagnosis and Treatment & Chronic Lymphocytic Leukemia Research & CAR-T cell therapy research. The author has an h-index of 5, co-authored 12 publications.
ORCID: 0000-0002-6431-4362Papers by this author
worksComparing the efficacy and safety of first-line treatments for chronic lymphocytic leukemia: a network meta-analysis
2024 · JNCI Journal of the National Cancer Institute · 3 citations
https://doi.org/10.1093/jnci/djae245
Axillary lymph node dissection plus radiotherapy may be an optimal strategy for patients with occult breast cancer
2022 · Journal of the National Cancer Center · 2 citations
https://doi.org/10.1016/j.jncc.2022.09.001
Research topics
topicsChat about Author
Papers
Chat
Click to start Chat